Klampatsa Astero, Haas Andrew R, Moon Edmund K, Albelda Steven M
Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Cancers (Basel). 2017 Sep 1;9(9):115. doi: 10.3390/cancers9090115.
Cancer immunotherapy has now become a recognized approach to treating cancers. In addition to checkpoint blockade, adoptive T cell transfer (ACT) using chimeric antigen receptors (CARs) has shown impressive clinical outcomes in leukemias and is now being explored in solid tumors. CARs are engineered receptors, stably or transiently transduced into T cells, that aim to enhance T cell effector function by recognizing and binding to a specific tumor-associated antigen. In this review, we provide a summary of CAR T cell preclinical studies and clinical trials for malignant pleural mesothelioma (MPM), a rare, locally invasive pleural cancer with poor prognosis. We list other attractive potential targets for CAR T cell therapy for MPM, and discuss augmentation strategies of CAR T cell therapy with other forms of immunotherapy in this disease.
癌症免疫疗法现已成为一种公认的癌症治疗方法。除了检查点阻断疗法外，使用嵌合抗原受体（CAR）的过继性T细胞转移（ACT）在白血病治疗中已显示出令人瞩目的临床效果，目前正在实体瘤治疗中进行探索。CAR是经过工程改造的受体，可稳定或瞬时转导至T细胞中，旨在通过识别并结合特定的肿瘤相关抗原来增强T细胞效应功能。在本综述中，我们总结了针对恶性胸膜间皮瘤（MPM）的CAR T细胞临床前研究和临床试验，MPM是一种罕见的、局部侵袭性胸膜癌，预后较差。我们列出了MPM的CAR T细胞疗法其他有吸引力的潜在靶点，并讨论了在该疾病中CAR T细胞疗法与其他形式免疫疗法的联合策略。
